Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia Wants To Link Regulatory Review Of CDx And Associated Drugs

Executive Summary

Therapeutic Goods Administration proposals say the review of companion diagnostics and their corresponding drugs should be linked.

You may also be interested in...



Views Differ On Australian Proposal To Link Review Of CDx With Drugs

An Australian proposal to establish a regulatory framework for companion diagnostics has drawn a mixed response from pharmaceutical, biotech and medtech companies on issues like concurrent evaluation, product classification and unique identification.

Australia Wants To Link Regulatory Review Of CDx And Associated Drugs

Therapeutic Goods Administration proposals say the review of companion diagnostics and their corresponding drugs should be linked.

Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug

The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT123508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel